Sanofi, Amgen get solid FDA reviews on PSCK9 meds; J&J files for cancer med approval;

> Sanofi ($SNY) and Regeneron's ($REGN) anticholesterol drug Praluent effectively lowers "bad" LDL cholesterol and is reasonably well-tolerated, FDA staff reviewers said ahead of a Tuesday advisory panel meeting on the drug. Report

> Amgen's ($AMGN) PCSK9 cholesterol fighter Repatha lowered LDL with no red-flag safety problems, FDA staffers concluded in a review before Wednesday's advisory committee meeting on the med. Report

> Johnson & Johnson ($JNJ) said it applied for FDA approval for the "breakthrough"-designated blood cancer drug daratumumab, developed with Genmab. Report

> An FDA panel of experts backed approval of a controversial women's libido pill from Sprout, on the condition that the agency require postmarketing safety studies. Report

> London-based Four Communications snapped up the healthcare agency MSA Media--which counts Novartis ($NVS) and Bayer among its clients--to bolster its media-planning capabilities in the field. Report

And Finally... Botulinum toxin injections, sold as Botox and other brands, could be effective in two forms of neuropathy, a pain journal study found. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?